Breaking

Why India rejected a patent application for shorter drug-resistant TB treatment | Explained

The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care

· 10/29/2026, 7:52:09 AM· 2 min read
Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
The decision could open the door to greater generic competition, but its impact on treatment costs will depend on drug availability, pricing, and access to care
Read original story →

Related stories